Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Kevin Charles Gorman Sells 2,274 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Kevin Charles Gorman sold 2,274 shares of Neurocrine Biosciences stock in a transaction on Monday, February 10th. The stock was sold at an average price of $118.37, for a total transaction of $269,173.38. Following the completion of the transaction, the director now directly owns 519,074 shares in the company, valued at $61,442,789.38. This represents a 0.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Kevin Charles Gorman also recently made the following trade(s):

• On Friday, January 31st, Kevin Charles Gorman sold 2,707 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $152.92, for a total value of $413,954.44.
• On Monday, January 27th, Kevin Charles Gorman sold 146,105 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $149.46, for a total transaction of $21,836,853.30.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock opened at $117.18 on Thursday. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.95 and a fifty-two week high of $157.98. The stock’s fifty day moving average is $138.49 and its two-hundred day moving average is $131.02. The firm has a market capitalization of $11.86 billion, a P/E ratio of 35.62 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. On average, equities analysts forecast that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Golden State Wealth Management LLC acquired a new stake in shares of Neurocrine Biosciences during the 4th quarter worth approximately $25,000. Huntington National Bank increased its position in shares of Neurocrine Biosciences by 73.5% during the 4th quarter. Huntington National Bank now owns 229 shares of the company’s stock worth $31,000 after purchasing an additional 97 shares during the last quarter. Brooklyn Investment Group raised its holdings in Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after buying an additional 115 shares during the period. Blue Trust Inc. lifted its position in Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after buying an additional 220 shares during the last quarter. Finally, Lindbrook Capital LLC boosted its stake in Neurocrine Biosciences by 53.5% during the fourth quarter. Lindbrook Capital LLC now owns 373 shares of the company’s stock worth $51,000 after buying an additional 130 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on NBIX. Deutsche Bank Aktiengesellschaft started coverage on shares of Neurocrine Biosciences in a report on Tuesday. They set a “hold” rating and a $138.00 price objective on the stock. UBS Group raised their price target on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a “buy” rating in a research report on Thursday, January 30th. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. Canaccord Genuity Group reduced their target price on shares of Neurocrine Biosciences from $172.00 to $163.00 and set a “buy” rating for the company in a report on Friday, February 7th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $166.90.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.